1.Williams WW, Taheri D, Tolkoff-Rubin N, et al. Clinical role of the renal transplant biopsy. Nat Rev Nephrol. 2012;8(2):110–121.
2. Zhang J, Qiu J, Chen GD, et al. Etiological analysis of graft dysfunction following living kidney transplantation: a report of 366 biopsies. Ren Fail. 2018; DOI: 10.1080/0886022X.2018.1455592.
3.El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9(3):527–535.
4.Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med. 2002;347(2):103–109.
5.Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephro. 2010;5(12):2363–2372.
6.McDonald SP, Russ GR. Recurrence of IgA nephropathy among renal allograft recipients from living donors is greater among those with zero HLA mismatches. Transplantation. 2006;82(6):759–762.
7.Moroni G, Longhi S, Quaglini S, et al. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol Dial Transplant. 2013;28(5):1305–1314.
8.Kim SJ, Koo HM, Lim BJ, et al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLOS One. 2012;7(7):e40495.
9.Lv J, Shi S, Xu D, et al. Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013;62(5):891–899.
10.Hariharan S, Peddi VR, Savin VJ, et al. Recurrent and de novo renal diseases after renal transplantation: a report from the renal allograft disease registry. Am J Kidney Dis. 1998;31(6):928–931.
11.Floege J, Gröne HJ. Recurrent IgA nephropathy in the renal allograft: not a benign condition. Nephrol Dial Transplant. 2013;28(5):1070–1073.
12.Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(3):S1–155.
13.Kidney disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. 2012;2:139–274.
14. Foundation NK. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl1):S1–266.
15.Lai KN. Pathogenesis of IgA nephropathy. Nat Rev Nephrol. 2012;8(5):275–283.
16.Nijim S, Vujjini V, Alasfar S, et al. Recurrent IgA nephropathy after kidney transplantation. Transplant Proc. 2016;48(8):2689–2694.
17.Floege J. Recurrent IgA nephropathy after renal transplantation. Semin Nephrol. 2004;24(3):287–291.
18.Avasare RS, Rosenstiel PE, Zaky ZS, et al. Predicting post-transplant recurrence of IgA nephropathy: the importance of crescents. Am J Nephrol. 2017;45(2):99–106.
19.Choy BY, Chan TM, Lo SK, et al. Renal transplantation in patients with primary immunoglobulin A nephropathy. Nephrol Dial Transplant. 2003;18(11):2399–2404.
20. Ortiz F, Gelpi R, Koskinen P, et al. IgA nephropathy recurs early in the graft when assessed by protocol biopsy. Nephrol Dial Transplant. 2012;27(6):2553–2558.
21.Radford MG, Donadio JV, Bergstralh EJ, et al. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997;8(2):199–207.
22.Goto M, Wakai K, Kawamura T, et al. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant. 2009;24(10):3068–3074.
23.Berthoux F, Mohey H, Laurent B, et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011;22(4):752–761.
24.Shu D, Xu F, Su Z, et al. Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study[J]. BMC Nephrol. 2017;18(1):11.
25. Platt JF, Rubin JM, Ellis JH. Distinction between obstructive and nonobstructive
pyelocaliectasis with duplex Doppler sonography. AJR. 1989;153(5):997–1000.
26.Lee SM, Rao VM, Franklin WA, et al. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982;13(4):314–322.
27.Hisano S, Joh K, Katafuchi R, et al. Reproducibility for pathological prognostic parameters of the Oxford classification of IgA nephropathy: a Japanese cohort study of the Ministry of Health, Labor and Welfare. Clin Exp Nephrol. 2017;21(1):92–96.
28.Barbour SJ, Espino-Hernandez G, Reich HN, et al. The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int. 2016;89(1):167–175.
29.Lee H, Yi SH, Seo MS, et al. Validation of the Oxford classification of IgA nephropathy: a single-center study in Korean adults. Korean J Intern Med. 2012;27(3):293–300.
30.Tanaka S, Ninomiya T, Katafuchi R, et al. Development and validation of a prediction rule using the Oxford classification in IgA nephropathy. Clin J Am Soc Nephrol. 2013;8(12):2082–2090.
31. Trimarchi H, Barratt J, Cattran D C, et al. Oxford Classification of IgA nephropathy 2016-the role of crescentic lesions: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014.
32.Lee HJ, Choi SY, Jeong KH, et al. Association of C1q deposition with renal outcomes in IgA nephropathy. Clin Nephrol. 2013;80(2):98–104.
33.Nishiwaki H, Hasegawa T, Nagayama Y, et al. Absence of mesangial C1q deposition is associated with resolution of proteinuria and hematuria after tonsillectomy plus steroid pulse therapy for immunoglobulin A nephropathy. Nephron. 2015;130(1):1–7.
34.Andrade-Sierra J, Rojas-Campos E, Cardona-Muñoz E, et al. Early steroid withdrawal in recipients of a kidney transplant from a living donor: experience of a single Mexican center. Transplant Proc. 2016;48(1):42–49.
35.Cantarovich D, Rostaing L, Kamar N, et al. Early corticosteroid avoidance in kidney transplant recipients receiving ATG-F induction: 5-year actual results of a prospective and randomized study. Am J Transplant. 2014;14(11):2556–2564.
36.Ponticelli C, Glassock RJ. IgA nephritis with declining renal function: treatment with corticosteroids may be worthwhile. J Am Soc Nephrol. 2015;26(9):2071–2073.
37.Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-termresults of a randomized, controlled trial. J Am Soc Nephrol. 2004;15(1):157–163.
38.Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgAnephropathy. N Engl J Med. 2015;373(23):2225–2236.
39.Hotta K, Fukasawa Y, Akimoto M, et al. Tonsillectomy ameliorates histological damage of recurrent immunoglobulin A nephropathy after kidney transplantation. Nephrology. 2013;18(12):808–812.
40.Ushigome H, Suzuki T, Fujiki M, et al. Efficacy of tonsillectomy for patients with recurrence of IgA nephropathy after kidney transplantation. Clin Transpl. 2009;23(S20):17–22.